Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Lung Neoplasms 12Carcinoma, Hepatocellular 8Small Cell Lung Carcinoma 7Cholangiocarcinoma 7Neoplasms 6Carcinoma 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Neoplasms by Site 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasms by Histologic Type 2Liver Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Bile Duct Neoplasms 2Adenocarcinoma 2Vaccinia 1Unresectable Hepatocellular Carcinoma 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

tremelimumab 1durvalumab 1Liver Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypertension, Portal × durvalumab × 30 days × Clear all
NCT05027425 2026-05-06

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

University of Cincinnati

Phase 2 Terminated
8 enrolled 9 charts
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡